Robert Eno Joins HeartBeam as President, Bringing Decades of Leadership Experience to the Table

HeartBeam Inc. (NASDAQ: BEAT), a groundbreaking cardiac technology company, is delighted to welcome Robert Eno to their executive team in the newly created position of President. With a history of developing and launching cutting-edge medical technologies, Eno will spearhead the commercialization of the revolutionary HeartBeam AIMI™ and HeartBeam AIMIGo™ platforms, which provide the world’s first and only 3D-vector electrocardiogram (VECG) for heart attack detection anytime, anywhere.

I am honored to be a part of the HeartBeam team as we enter a new and exciting commercial phase. HeartBeam’s innovative technology is poised to make a substantial impact in the lives of millions of people who suffer from cardiac-related issues. I am confident that with the help of HeartBeam, we can establish our platform as the new gold standard of ambulatory-based cardiology. I’m thrilled to be a part of this remarkable journey!

Mr. Eno is an innovative and ambitious senior executive with an impressive 28 years of experience. He has developed successful market strategies for numerous pioneering products such as noninvasive FFRCT diagnostic for coronary artery disease, laser cataract surgery, scanning retinal laser photocoagulation, and intravascular brachytherapy. Most recently, Mr. Eno served as Chief Executive Officer of Preview Medical Inc., a diagnostic apparatus company that creates real-time, in vivo tissue classification for solid tumor cancers using exclusive optical signals and machine learning. Prior to that, he was Senior Vice President of Marketing for HeartFlow, Inc., managing all facets of the marketing and product teams for a personalized, noninvasive testing for heart disease, including its inaugural product, HeartFlow FFRCT. He has also held senior marketing and sales executive positions at OptiMedica, NeoGuide Systems, and Avantec Vascular.

We are thrilled to welcome Rob to our leadership team and are confident that his expertise and experience in bringing innovative medical technology products to market will help us to accelerate our company growth. HeartBeam CEO and Founder Branislav Vajdic, Ph.D. is eager to expand our portfolio pipeline and believes that Rob’s addition to our team will support our journey towards commercialization.

About HeartBeam, Inc.

HeartBeam Inc. (NASDAQ: BEAT) is revolutionizing cardiac care with the world’s first 3D-vector ECG platform. This innovative technology streamlines vector electrocardiography (VECG) and provides an effective solution for heart attack detection anytime, anywhere. HeartBeam’s two patented products, AIMI™ and AIMIGo™, are designed to expedite care and help patients and clinicians identify heart attacks with greater accuracy. AIMI™ is software for acute care settings that quickly compares baseline and symptomatic 12-lead ECG readings, while AIMIGo™ is a pocket-sized ECG device connected to a cloud-based diagnostic system for remote use. Although both products have yet to be cleared by the FDA for marketing, HeartBeam is poised to become a leader in cardiac technology.

Leave a Comment